This trial will assess the long-term safety of ribociclib when used in combination with other drugs in participants who have already benefited from the treatment.
1 Primary · 1 Secondary · Reporting Duration: Up to 5 years
137 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · Phase 4
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: